Developing a peer-led approach to assess the oral health needs and experiences of people in prison and on release - Nature
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
BackgroundGlobally, an estimated 11.5 million people are held in prisons, and in most countries the prison population is increasing [1]. People in prison experience multiple disadvantages such as prior experience of homelessness, substance use, mental ill-health, and higher exposure to trauma and abuse [2,3,4]. They face significantly poorer mental and physical health compared with the general population [5]. Whilst these inequalities are partly due to higher health needs on entering prison, the prison system itself can contribute to poor health due to structural and environmental barriers [6]. These challenges persist for individuals released from prison, who often face difficulties navigating community healthcare and experience interruptions in care [7]. The health inequalities people in prison face extend to oral health, they have a higher prevalence of untreated dental decay and periodontal disease, and the prevalence of dental infections is five times greater than in the general population [8,9,10]. People in prison are also more likely to suffer from substance use disorders, which is associated with poor oral health [11, 12].
This article is an excerpt. To read the full content, visit the original source. Nature
Related articles
ADHERE REAL Study to Assess Real-World Effectiveness of Efgartigimod in CIDP - NeurologyLive
News|Articles|September 30, 2026 A new study will follow adults with chronic inflammatory demyelinating polyradiculoneuropathy who start subcutaneous efgartigimod in routine practice in the US and Germany. A prospective, multicenter real-world study, dubbed ADHERE REAL (NCT07264426), will evaluate the effectiveness of subcutaneous efgartigimod PH20 (Vyvgart Hytrulo; argenx) in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study will also characterize patients' treatment journeys and health care resource utilization.1Efgartigimod is an FDA-approved, human IgG1 antibody Fc fragment that blocks the neonatal Fc receptor (FcRn), reducing IgG recycling and lowering circulating IgG levels. Presented at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, held September 29 to October 2, in Orlando, Florida, ADHERE REAL is intended to extend findings from the registrational ADHERE trial into routine clinical practice. Presented by lead author Jana Zschüntzsch, MD, senior consultant for neurology at University Medical Center Göttingen, the study will enroll adults with CIDP across the US and Germany.
Bioengineer.org | Viral blips during HIV therapy are common and rarely signal treatment failure, Swedish study finds - European AIDS Treatment Group
Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.
European Medical Journal | HIV linked to early signs of heart dysfunction - European AIDS Treatment Group
European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.
0 comments
No comments yet. Be the first to share your thoughts!